Clinical Relevance of +936 C>T and C.233C>T Polymorphisms in Chronic Lymphocytic Leukemia

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2020 Jun 27

PMID 32585853

Citations 3

Authors

Sandra Ballester

Begona Pineda

Patricia Rodrigues

Eduardo Tormo

Maria Jose Terol

Pilar Eroles

Affiliations

Soon will be listed here.

Abstract

Angiogenesis process contributes to the pathogenesis of B-cell chronic lymphocytic leukemia (B-CLL) being the levels of VEGFA and bFGF higher in patients than in healthy controls. Our aim was to evaluate the implication of angiogenesis factors genetic variants in the predisposition to B-CLL and their association with clinical factors and survival. We performed a population-based case-control study in 224 Spanish B-CLL patients and 476 healthy randomly selected controls to evaluate susceptibility to developing B-CLL. Six polymorphisms were evaluated: rs1109324, rs1547651, rs3025039 (+936 C>T), rs833052 of the gene, rs1449683 (c.233C>T) of the gene and (-710 C>T) of the gene. The association between clinical parameters and patient outcome was analyzed. Carriers of the CT/TT variants of rs3025039 showed a significant protective effect against developing B-CLL. The CT/TT variants of rs1449683 show a tendency towards the development of the disease and the same variants associated significantly with higher genetic risk and with reduced disease free survival. Moreover, the association persisted in the early-stage disease subgroup. Our study provides evidence of the protective effect of the T/- rs3025039 variant against B-CLL development and the association of CT/TT variants of the rs1449683 gene with genetic risk and an adverse survival.

Citing Articles

Super-Enhancer-Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients.

Liang X, Meng Y, Li C, Liu L, Wang Y, Pu L Front Genet. 2022; 13:1001364.

PMID: 36186463 PMC: 9521409. DOI: 10.3389/fgene.2022.1001364.

Genetic Variants Interplay in Genetic Susceptibility to Non-Melanocytic Skin Cancer.

Scola L, Bongiorno M, Forte G, Aiello A, Accardi G, Scrimali C Genes (Basel). 2022; 13(7).

PMID: 35886018 PMC: 9317818. DOI: 10.3390/genes13071235.

Study of the Association between Polymorphisms and the Risk of Coronary Artery Disease in Koreans.

Ko E, Kim I, Lee J, Park H, Park H, Kim S J Pers Med. 2022; 12(5).

PMID: 35629182 PMC: 9144104. DOI: 10.3390/jpm12050761.

References

Smolej L, Andrys C, Pekova S, Schwarz J, Belada D, Zak P . Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia. Haematologica. 2006; 91(10):1432-3. View

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P . The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat. 2012; 133(2):769-78. DOI: 10.1007/s10549-012-1980-1. View

Hu K, Zhang Y, Wang R, Li G, Li G, Zhang D . Current evidence on VEGF+405G/C polymorphism and malignancy susceptibility: a meta-analysis involving 30 studies. Twin Res Hum Genet. 2012; 15(4):496-502. DOI: 10.1017/thg.2012.34. View

Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E . A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2001; 37(6):443-8. DOI: 10.1159/000054076. View

Mohammed Basabaeen A, Abdelgader E, Ahmed Babekir E, Abdelrahim S, Eltayeb N, Altayeb O . TP53 Gene 72 Arg/Pro (rs1042522) Single Nucleotide Polymorphism Contribute to Increase the Risk of B-Chronic Lymphocytic Leukemia in the Sudanese Population. Asian Pac J Cancer Prev. 2019; 20(5):1579-1585. PMC: 6857868. DOI: 10.31557/APJCP.2019.20.5.1579. View

Wrobel T, Mazur G, Dzietczenia J, Gebura K, Kuliczkowski K, Bogunia-Kubik K . VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma. Biomed Res Int. 2013; 2013:159813. PMC: 3755428. DOI: 10.1155/2013/159813. View

Jain L, Vargo C, Danesi R, Sissung T, Price D, Venzon D . The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther. 2009; 8(9):2496-508. PMC: 2751847. DOI: 10.1158/1535-7163.MCT-09-0302. View

Heist R, Zhai R, Liu G, Zhou W, Lin X, Su L . VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(6):856-62. DOI: 10.1200/JCO.2007.13.5947. View

Folkman J . Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285(21):1182-6. DOI: 10.1056/NEJM197111182852108. View

10.

Schulz S, Kohler K, Schagdarsurengin U, Greiser P, Birkenmeier G, Muller-Werdan U . The human FGF2 level is influenced by genetic predisposition. Int J Cardiol. 2005; 101(2):265-71. DOI: 10.1016/j.ijcard.2004.03.049. View

11.

Carpini J, Karam A, Montgomery L . Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010; 13(1):43-58. DOI: 10.1007/s10456-010-9163-3. View

12.

Brogan I, Khan N, Isaac K, Hutchinson J, Pravica V, Hutchinson I . Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum Immunol. 2000; 60(12):1245-9. DOI: 10.1016/s0198-8859(99)00132-9. View

13.

Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher T . A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 2003; 106(4):468-471. DOI: 10.1002/ijc.11238. View

14.

Zhai R, Liu G, Asomaning K, Su L, Kulke M, Heist R . Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis. 2008; 29(12):2330-4. PMC: 2639251. DOI: 10.1093/carcin/bgn210. View

15.

Reis A, Alcantara K, de Farias D, Dos Anjos L, Rodrigues D, Pedrino G . The influence of MTHFR C677T polymorphism in chronic lymphocytic leukemia. Electrophoresis. 2019; 40(12-13):1715-1718. DOI: 10.1002/elps.201800402. View

16.

Molica S, Vitelli G, Levato D, Ricciotti A, Digiesi G . Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer. 2002; 86(1):31-5. PMC: 2746542. DOI: 10.1038/sj.bjc.6600022. View

17.

Vagner S, Gensac M, Maret A, Bayard F, Amalric F, Prats H . Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. Mol Cell Biol. 1995; 15(1):35-44. PMC: 231905. DOI: 10.1128/MCB.15.1.35. View

18.

Wolowiec D, Dybko J, Wrobel T, Urbaniak-Kujda D, Jazwiec B, Tomaszewska-Toporska B . Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm. 2006; 2006(3):42394. PMC: 1592593. DOI: 10.1155/MI/2006/42394. View

19.

Jevtovic-Stoimenov T, Cvetkovic T, Despotovic M, Basic J, Cvetkovic J, Marjanovic G . The influence of TNF alpha -308 G/A polymorphism on oxidative stress in patients with chronic lymphocytic leukemia. Leuk Res. 2017; 54:66-72. DOI: 10.1016/j.leukres.2017.01.018. View

20.

Kay N, Bone N, Tschumper R, Howell K, Geyer S, Dewald G . B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia. 2002; 16(5):911-9. DOI: 10.1038/sj.leu.2402467. View